Dr. Zhu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Yawkey 7e
Boston, MA 02114Phone+1 617-724-6193Fax+1 617-724-1137- Is this information wrong?
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Yale-New Haven Medical CenterResidency, Internal Medicine, 1995 - 1997
University of MinnesotaInternship, Internal Medicine, 1994 - 1995
Beijing Medical UniversityClass of 1982
Certifications & Licensure
MA State Medical License 2000 - 2025
Clinical Trials
- Epirubicin and Thalidomide in Treating Patients With Liver Cancer Start of enrollment: 2001 Dec 01
- Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Start of enrollment: 2005 Jan 01
- Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma Start of enrollment: 2004 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsCabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.Yau, T., Kaseb, A., Cheng, A., Qin, S., Zhu, A., Chan, S., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J., Ryoo, B., M...> ;The Lancet. Gastroenterology & Hepatology. 2024 Apr 1
- Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.Bin Fan, Ghassan K Abou-Alfa, Andrew X Zhu, Shuchi S Pandya, Hongxia Jia, Feng Yin, Camelia Gliser, Zhaowei Hua, Mohammad Hossain, Hua Yang> ;Cancer Chemotherapy and Pharmacology. 2024 May 1
- 3 citationsAlbumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the P...Masatoshi Kudo, Richard S Finn, Ann-Lii Cheng, Andrew X Zhu, Michel Ducreux, Peter R Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel> ;Liver Cancer. 2023 Oct 1
- Join now to see all
Journal Articles
- Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and OpportunitiesAndrew Zhu, MD, Frontiers in Immunology
- A Phase II and Biomarker Study of Sorafenib Combined with FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)Hui Zheng, Rakesh K Jain, Lipika Goyal, Andrew X Zhu, Clinical Cancer Research
Lectures
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular c...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D DayApril 19th, 2022- I-mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 9th, 2022
- I-mab Receives FDA Orphan Drug Designation for Its Novel Claudin 18.2 X 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric CancerMarch 3rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
